Ofloxacin otic solution

Drug Profile

Ofloxacin otic solution

Alternative Names: 0.3% Ofloxacin otic solution - Daiichi; DL 8280; Floxin Otic; Floxin Otic SINGLES

Latest Information Update: 04 Aug 2010

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Otitis externa; Otitis media

Most Recent Events

  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 10 May 2004 Daiichi has launched Floxin® Otic SINGLES™ for common ear infections in the USA
  • 01 Mar 2004 Data from a media release have been added to the adverse events and Bacterial Infections therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top